Table 1.
Demographic and clinical characteristics
| Patient | Age (y) | Race | Comorbidities | Etiology of ED | Previous therapy | Previous IPP surgeries, n | IPP duration (y) | Presentation with failure since last IPP surgery (mo) |
|---|---|---|---|---|---|---|---|---|
| 1 | 72 | AA | HTN, DSL, gout, depression | CVOD | PDE5i, IPP | 1 | 3 | 10 |
| 2 | 77 | AA | HTN, DSL, DM, arthritis | RRP | PDE5i, ICI, IPP | 3 | 17 | Immediate |
| 3 | 63 | CA | depression, epilepsy | CVOD | PDE5i, ICI, MUSE, IPP | 3 | 18 | Immediate |
| 4 | 67 | AA | DSL, IHD, DM | CVOD | PDE5i, ICI, IPP | 4 | 31 | Immediate |
| 5 | 56 | AA | none | RRP | PDE5i, ICI, IPP | 1 | 5 | 14 |
AA = African American; CA = Caucasian; CVOD = corporal veno-occlusive disease; DM = diabetes mellitus; DSL = dyslipidemia; ED = erectile dysfunction; HTN = hypertension; ICI = intracavernosal injection; IHD = ischemic heart disease; IPP = inflatable penile prosthesis; MUSE = medicated urethral system for erection; PDE5i = phosphodiesterase type 5 inhibitor; RRP = retropubic radical prostatectomy.